Jin Caibao, Yang Bin
Department of Thoracic Oncology, Hubei Cancer Hospital, Wuhan, China.
Case Rep Oncol. 2021 Apr 6;14(1):659-663. doi: 10.1159/000514050. eCollection 2021 Jan-Apr.
The coexistence of lung cancer and pulmonary tuberculosis (TB) is rare, and the clinical and radiological features are always similar between lung cancer and pulmonary TB. In the present case, a non-small cell lung cancer patient with an epidermal growth factor receptor (EGFR)-sensitive mutation was diagnosed with pulmonary TB during the treatment of tyrosine kinase inhibitor (TKI) because of the discrepant and confusing responses among different lesions. Therefore, we should combine clinical and radiological characteristics with pathological and microbiological tests to confirm the diagnosis of TB or lung cancer. It is a safe and selectable therapeutic strategy to treat EGFR mutant lung cancer patients with active TB using anti-TB medications and TKIs simultaneously.
肺癌与肺结核（TB）并存的情况较为罕见，肺癌和肺结核的临床及影像学特征往往相似。在本病例中，一名患有表皮生长因子受体（EGFR）敏感突变的非小细胞肺癌患者在酪氨酸激酶抑制剂（TKI）治疗期间因不同病灶间反应不一致且令人困惑而被诊断为肺结核。因此，我们应将临床和影像学特征与病理及微生物学检查相结合，以确诊肺结核或肺癌。对于患有活动性肺结核的EGFR突变型肺癌患者，同时使用抗结核药物和TKI进行治疗是一种安全且可选择的治疗策略。
